Katherine Stueland Sells 10,501 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 10,501 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $60.77, for a total value of $638,145.77. Following the completion of the transaction, the chief executive officer owned 104,372 shares in the company, valued at $6,342,686.44. The trade was a 9.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Katherine Stueland also recently made the following trade(s):

• On Tuesday, June 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The shares were sold at an average price of $53.77, for a total value of $195,669.03.
• On Wednesday, April 29th, Katherine Stueland sold 2,172 shares of GeneDx stock. The stock was sold at an average price of $65.19, for a total value of $141,592.68.
• On Thursday, March 26th, Katherine Stueland sold 46,933 shares of GeneDx stock. The stock was sold at an average price of $63.17, for a total value of $2,964,757.61.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $59.01 on Friday. The company has a market capitalization of $1.75 billion, a PE ratio of -22.02 and a beta of 1.96. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The business has a fifty day moving average price of $54.25 and a two-hundred day moving average price of $86.49. GeneDx Holdings Corp. has a 1 year low of $32.21 and a 1 year high of $170.87.

GeneDx (NASDAQ:WGS) last announced its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The business had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same period in the prior year, the business earned ($0.23) earnings per share. Analysts forecast that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

Analyst Ratings Changes

WGS has been the topic of a number of research analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $130.00 target price (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Zacks Research cut shares of GeneDx from a “strong-buy” rating to a “hold” rating in a report on Friday, April 24th. Weiss Ratings downgraded GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. Jefferies Financial Group set a $150.00 price objective on GeneDx in a research note on Monday, February 23rd. Finally, Guggenheim reduced their price objective on GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $96.43.

Hedge Funds Weigh In On GeneDx

Large investors have recently modified their holdings of the company. Bank of America Corp DE increased its holdings in GeneDx by 77.5% during the 1st quarter. Bank of America Corp DE now owns 234,606 shares of the company’s stock worth $15,066,000 after acquiring an additional 102,456 shares during the period. California State Teachers Retirement System boosted its holdings in GeneDx by 31.2% in the 1st quarter. California State Teachers Retirement System now owns 25,045 shares of the company’s stock valued at $1,608,000 after purchasing an additional 5,951 shares during the period. Ashford Capital Management Inc. grew its position in shares of GeneDx by 31.9% during the 1st quarter. Ashford Capital Management Inc. now owns 174,512 shares of the company’s stock valued at $11,207,000 after purchasing an additional 42,186 shares in the last quarter. Quantinno Capital Management LP grew its position in shares of GeneDx by 99.2% during the 1st quarter. Quantinno Capital Management LP now owns 3,810 shares of the company’s stock valued at $245,000 after purchasing an additional 1,897 shares in the last quarter. Finally, First Light Asset Management LLC bought a new position in shares of GeneDx in the first quarter worth $15,601,000. 61.72% of the stock is currently owned by institutional investors.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Negative Sentiment: Multiple law firms are advertising a securities class action against GeneDx, with a lead-plaintiff deadline of August 3, 2026, alleging material misstatements and omissions about the viability of the Fabric Genomics acquisition. GeneDx securities fraud class action lawsuit filed
• Negative Sentiment: Several follow-up notices emphasize the alleged 49% stock decline after GeneDx’s Q1 2026 earnings report and a 94% write-off related to the acquisition, reinforcing concerns about execution and disclosure risk. Hagens Berman class action alert
• Neutral Sentiment: GeneDx disclosed insider sales by CEO Katherine Stueland and CFO Kevin Feeley, but the filings say the shares were sold to cover tax withholding obligations tied to vesting equity awards, which makes the transactions less alarming on their own. CEO SEC filing CFO SEC filing
• Positive Sentiment: GeneDx appointed Mark Gardner as company president, a leadership move that could improve execution and strategic focus over time. GeneDx appoints new president

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.